Business
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST NEW YORK, March 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ)
About this update from Pavmed Inc.
[{"type":"text","content":"Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST\nNEW YORK, March 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (\"Lucid\") and Veris Health Inc. (\"Veris\"), and presented financial results for the year ended December 31, 2022.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast\nThe webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 877-550-1858 and international listeners should dial 1-848-488-9160. All listeners should provide the operator with the conference call name \"PAVmed, Inc. Business Update Conference Call\" to join.\nThose seeking further details on Lucid are encouraged to visit the company's website at luciddx.com to view the webcast of its business update call held yesterday, and its corresponding press release.\nBusiness Update Highlights\n\"Over the past two months, the PAVmed team has executed on its strategic restructuring plan to protect long-term shareholder interests during challenging market conditions by tightly focusing its efforts and resource allocation on near-term commercial activities and milestones,\" said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. \"The plan is working and appears to have been right-sized—extending cash runway while assuring the commercial efforts are adequately resourced. Lucid continues to deliver steady EsoGuard test volume growth through organic sales and now high-volume testing events and is gaining traction with commercial payors. Veris' momentum is accelerating with an exciting commercial product, strong customer interest and a powerful business model which is not dependent on securing third-party reimbursement. I am proud how the team has battled through these challenges and emerged stronger with a bright commercial future for what remains a diversified portfolio.\"\nHighlights from the fourth quarter and recent weeks include:\nIn January 2022, PAVmed launched a strategic restructuring initiative desig...